1315 Capital is a private investment firm with over $825 million under management that provides expansion and growth capital to commercial-stage healthcare services, medical technology, and therapeutics / pharmaceutical services companies. The firm targets markets where high-quality management teams can rapidly scale platform companies into large and important businesses that positively impact patients, physicians, and the broader healthcare system.
- Healthcare
- Medical Devices
- Biotechnology
- Pharmaceuticals
- Diagnostics
- Insurance
- Clinical Research
- Medical Technology
- Biotherapeutics
- Employee Benefits
Leadership
| Name | Title | ||
|---|---|---|---|
| Matthew Reber | Partner |
in/matthew-reber-9942b3
|
|
| Partner |
|
||
| Partner |
|
|
|
| Vice President |
|
|
|
| Founding Partner |
|
|
|
| Founding Partner |
|
|
Recent Transactions involving 1315 Capital
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics |
Primrose Bio |
1315 Capital |
Biotechnology | |
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →